In a cohort study of 412 women with MS, 10-fold lower AMH levels were linked with accelerated reduction of gray matter volume in both a cross-sectional analysis (change in cortical gray matter: −7.44 mm3; p = 0.041) and a longitudinal analysis with up to 10 years of follow-up (change in cortical gray matter: −4.55 mm3; p = 0.062) and increased EDSS score (cross-sectional analysis: 0.43-point increase [p = 0.003]; longitudinal analysis: 0.27-point increase [p = 0.006]) (22). The gene discussed is AMH; the disease is myeloid sarcoma.